文献速递浆细胞疾病

全口服伊沙佐米、环磷酰胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤的2期研究

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
PubMed 文献 · Br J Haematol · 2018-11-20

这项2期研究评估全口服伊沙佐米、环磷酰胺和地塞米松(ICd)方案治疗复发/难治性多发性骨髓瘤(RRMM),共纳入78例患者(中位年龄63.5岁),总体缓解率(ORR)为48%(≥非常好的部分缓解率16%),≥65岁与<65岁患者ORR分别为64%和32%,中位无进展生存期(PFS)为14.2个月,方案耐受性良好。

要点

  • 全口服ICd方案治疗RRMM的ORR为48%,≥非常好的部分缓解率为16%。
  • ≥65岁患者ORR为64%,<65岁患者为32%。
  • 中位随访15.2个月,中位PFS为14.2个月。

核心结论

  • 全口服伊沙佐米、环磷酰胺和地塞米松方案在复发/难治性多发性骨髓瘤中显示出疗效且耐受性良好。

研究设计与样本

  • 2期研究,纳入78例复发/难治性多发性骨髓瘤患者,中位年龄63.5岁。
  • 给药方案:28天为一周期,第1、8、15天口服伊沙佐米4 mg和环磷酰胺300 mg/m²,第1、8、15、22天口服地塞米松40 mg。
  • 主要终点为总体缓解率(ORR)。

主要发现

  • 截至数据截止,患者中位接受12个治疗周期,31%仍在治疗中。
  • ORR为48%,其中≥非常好的部分缓解(≥VGPR)率为16%。
  • ≥65岁与<65岁患者的ORR分别为64%和32%,≥VGPR率分别为25%和16%。
  • 中位随访15.2个月,中位无进展生存期(PFS)为14.2个月。
  • ≥65岁与<65岁患者的中位PFS分别为18.7个月和12.0个月(风险比0.62,P=0.14)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m2 on days 1, 8 and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28-day cycles. The primary endpoint was overall response rate (ORR). Seventy-eight patients were enrolled (median age 63·5 years). At data cut-off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and <65 years (25% and 16% ≥VGPR), respectively. At a median follow-up of 15·2 months, median progression-free survival (PFS) was 14·2 months, with a trend towards better PFS in patients aged ≥65 years vs. <65 years (median 18·7 months vs. 12·0 months; hazard ratio 0·62, P = 0·14). ICd was well tolerated. The most common treatment-emergent adverse events were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), and thrombocytopenia (22%); 10 patients (13%) had peripheral neuropathy (one grade 3). This study is registered at ClinicalTrials.gov (NCT02046070).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kumar SK, Grzasko N, Delimpasi S, et al. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. Br J Haematol. 2018. PMID: 30460684. doi:10.1111/bjh.15679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。